Recently, we identified antibodies against carbamylated proteins (anti-CarP) in the serum of RA patients and showed that the presence of these antibodies is predictive of worse disease progression in ACPA negative patients [14]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.